Phase II FANG™ in Advanced Melanoma

Status Terminated

Clinical Trial Summary

Preliminary studies with a variety of vaccines suggest target accessibility (potential immunogenicity) in a variety of solid tumors to immune directed approaches. In an effort to overcome limitations of immunostimulatory cancer vaccines, the investigators have designed a novel autologous vaccine to address inability to fully identify cancer associated antigens, antigen recognition by the immune system (i.e. antigen to immunogen), effector potency, and cancer-induced resistance. In an effort to overcome limitations of immunostimulatory cancer vaccines, the investigators designed a novel dual-modulatory autologous whole cell vaccine, Vigil™ (bi-shRNA furin and GMCSF Autologous Tumor Cell Vaccine), incorporating the rhGMCSF (recombinant human GMCSF) transgene and the bifunctional shRNAfurin (to block proprotein conversion to active TGFb1 and b2) to 1) address the inability to fully identify cancer associated antigens, 2) effect antigen recognition by the immune system (i.e. antigen to immunogen), 3) enhance effector potency, and 4) subvert endogenous cancer-induced immune resistance. The investigators have also completed the Phase I assessment of Vigil™ vaccine in 27 advanced solid tumor patients (1.0 x 10e7 or 2.5 x 10e7 cells/injection/month for a maximum of 12 vaccinations) who have not experienced any significant adverse effects following 131 vaccinations, including 4 patients with melanoma. Plasmid functionality, immune biomarker response, and preliminary evidence of anticancer activity have been observed. This is a Phase II study of intradermal autologous Vigil™ cancer vaccine (1.0 x 10e7 cells/injection; maximum of 12 vaccinations) in patients with stages IIIc and IV melanoma with biopsy accessible lesions to document blood and intratumoral immune responses and assess correlation with survival.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01453361
Study type	Interventional
Source	Gradalis, Inc.
Contact
Status	Terminated
Phase	Phase 2
Start date	October 2011
Completion date	March 22, 2016

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05039801` - IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors	Phase 1
Terminated	`NCT04894994` - FLX475 in Combination With Ipilimumab in Advanced Melanoma	Phase 2
Completed	`NCT01621490` - PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma	Phase 1
Recruiting	`NCT05098184` - Study on TIL for the Treatment of Advanced Melanoma	Early Phase 1
Completed	`NCT02177110` - A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or Metastatic Malignant Melanoma
Completed	`NCT00197912` - Dendritic Cell Based Therapy of Malignant Melanoma	Phase 1/Phase 2
Completed	`NCT04165967` - Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for Melanoma	Phase 1
Recruiting	`NCT04495257` - A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)	Phase 1
Recruiting	`NCT05968690` - Naltrexone and Propranolol Combined With Immunotherapy	Phase 1
Active, not recruiting	`NCT03200847` - Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma	Phase 1/Phase 2
Recruiting	`NCT05105100` - Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma
Completed	`NCT02171286` - The Oncopanel Pilot (TOP) Study	N/A
Recruiting	`NCT05120024` - Multicenter Study of Safety and Efficacy of Prolgolimab in Patients With Advanced Melanoma in Routine Clinical Practice
Active, not recruiting	`NCT04514484` - Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV	Phase 1
Active, not recruiting	`NCT04951583` - Fecal Microbial Transplantation Non-Small Cell Lung Cancer and Melanoma	Phase 2
Recruiting	`NCT06112808` - A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin	Phase 1
Recruiting	`NCT01614301` - Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma	Phase 1/Phase 2
Recruiting	`NCT04640545` - A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma	Phase 1
Active, not recruiting	`NCT03086174` - Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and Melanoma	Phase 1
Recruiting	`NCT03917069` - Nab-PCE vs PC for MM After Failure of Anti-PD-1	Phase 2